Multi Commodity Exchange of India (MCX) reported a strong performance in the September quarter of FY27, with net profit rising sharply by 130% year-on-year. Higher revenue and improved operating performance supported the company’s growth during the quarter.
The exchange’s net profit increased to ₹454.57 crore in Q2 FY27, compared with ₹197.47 crore in the corresponding quarter last year.
Revenue Climbs to ₹799.66 Crore
MCX’s revenue from operations nearly doubled during the quarter. It increased to ₹799.66 crore from ₹374.23 crore in Q2 of the previous financial year.
Operating performance also remained strong. EBITDA jumped to ₹611.24 crore against ₹243.63 crore a year earlier. The EBITDA margin improved to 76.4%, compared with 65.1% in the same period last year.
Strong Performance in the First Half of FY27
MCX also recorded healthy growth during the first six months of FY27.
- Revenue increased 100.8% to ₹1,502 crore.
- EBITDA grew 121.3% to ₹1,206 crore.
- Net profit rose 116.4% to ₹868 crore.
Trading activity remained an important growth driver. The average daily turnover in futures stood at ₹61,280 crore, while options turnover reached ₹10,96,529 crore during the first half.
MCX Invests ₹51.50 Crore in Coal Exchange Subsidiary
Alongside its financial results, MCX announced an additional investment of ₹51.50 crore in its subsidiary, MCX Coal Exchange of India Ltd.
Following this investment, the exchange’s total investment in the subsidiary increased to ₹52.50 crore.
SBI Securities Sets ₹3,633 Target Price
Brokerage firm SBI Securities has maintained a positive outlook on MCX and assigned a target price of ₹3,633.
The brokerage sees the possibility of around 14% upside during Samvat 2083. Its outlook is supported by expectations of continued activity in the commodity market, including higher participation and market volatility.
MCX Share Price Performance
MCX shares ended Tuesday, November 3, 2026, at ₹3,490.10, gaining 7.42% during the trading session.
The stock has delivered a return of approximately 19.82% over the past six months.
With strong quarterly earnings, higher trading activity and improving operating margins, MCX remains in focus following its Q2 FY27 results.
Disclaimer: This article is for news and informational purposes only. Brokerage targets and market expectations are not guaranteed returns. Investors should consult a qualified financial adviser before making investment decisions.
Pingback: Jhunjhunwala-Backed Concord Biotech Shares Fall 50%: Here's Why the Stock Price Halved - khabriuncle.in